全文获取类型
收费全文 | 955篇 |
免费 | 74篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 22篇 |
妇产科学 | 15篇 |
基础医学 | 138篇 |
口腔科学 | 11篇 |
临床医学 | 125篇 |
内科学 | 163篇 |
皮肤病学 | 14篇 |
神经病学 | 130篇 |
特种医学 | 27篇 |
外科学 | 98篇 |
综合类 | 10篇 |
一般理论 | 4篇 |
预防医学 | 140篇 |
眼科学 | 26篇 |
药学 | 41篇 |
中国医学 | 1篇 |
肿瘤学 | 61篇 |
出版年
2023年 | 5篇 |
2021年 | 26篇 |
2020年 | 22篇 |
2019年 | 20篇 |
2018年 | 37篇 |
2017年 | 11篇 |
2016年 | 19篇 |
2015年 | 25篇 |
2014年 | 24篇 |
2013年 | 54篇 |
2012年 | 62篇 |
2011年 | 69篇 |
2010年 | 30篇 |
2009年 | 26篇 |
2008年 | 49篇 |
2007年 | 55篇 |
2006年 | 47篇 |
2005年 | 58篇 |
2004年 | 49篇 |
2003年 | 43篇 |
2002年 | 49篇 |
2001年 | 17篇 |
2000年 | 9篇 |
1999年 | 7篇 |
1998年 | 12篇 |
1997年 | 17篇 |
1996年 | 15篇 |
1995年 | 15篇 |
1994年 | 6篇 |
1993年 | 8篇 |
1992年 | 8篇 |
1991年 | 8篇 |
1990年 | 15篇 |
1989年 | 8篇 |
1988年 | 14篇 |
1987年 | 10篇 |
1986年 | 7篇 |
1985年 | 5篇 |
1984年 | 9篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1979年 | 3篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1974年 | 4篇 |
1973年 | 4篇 |
1972年 | 3篇 |
1969年 | 3篇 |
1968年 | 4篇 |
1960年 | 3篇 |
排序方式: 共有1030条查询结果,搜索用时 46 毫秒
11.
Twenty-three cases of ductal carcinoma in situ (DCIS), ten of which had an associated invasive component, were studied for loss of heterozygosity (LOH) of microsatellite markers on chromosome 9p and the results compared with a panel of 20 invasive breast carcinomas. In addition to the gene encoding p16, chromosome 9p is also thought to contain other putative tumour-suppressor genes. If the three panels of breast tumours showed LOH of markers in this region this would suggest that such putative genes were important in breast carcinogenesis. By studying both preinvasive and invasive breast tumours, it should also be possible to gain further information about the relationship between lesions of a different stage and to determine whether DCIS is indeed a precursor of invasive ductal carcinoma. Levels of LOH were low in the invasive-only set of tumours. Surprisingly, considerably higher levels of loss were observed in the tumours with an in situ component. Also, much heterogeneity was observed between different DCIS ducts or invasive tumour and DCIS from the same case. 相似文献
12.
Elena N Klyushnenkova Jason Link Warren T Oberle James Kodak Cathleen Rich Arthur A Vandenbark Richard B Alexander 《Clinical cancer research》2005,11(8):2853-2861
The development of immunotherapy for prostate cancer based on the induction of autoimmunity to prostate tissue is very attractive because prostate is not a vital organ beyond the reproductive years. CD4 T cells play an important role in the development of antitumor immune responses, yet the identification of naturally processed MHC Class II-restricted epitopes derived from prostate differentiation antigens has not been described. To facilitate the search for prostate-specific antigen (PSA)-derived MHC class II-restricted peptides, we immunized mice transgenic for HLA-DRB1*1501 with human PSA and showed a robust dose-dependent immune response to the antigen. Screening a library of overlapping 20-mer peptides that span the entire PSA sequence identified two 20-mer peptides, PSA(171-190) and PSA(221-240), which were responsible for this reactivity. Immunization of DR2b transgenic mice with these peptides induced specific responses to the peptide and whole PSA. Identified peptides were used to stimulate CD4 T cells from HLA-DRB1*1501+ patients with a rare condition, granulomatous prostatitis, and who seem to have a preexisting immune response directed against the prostate gland. We previously showed a linkage of granulomatous prostatitis to HLA-DRB1*1501, suggesting that this disease may have an autoimmune etiology. Peptide-specific CD4 T-cell lines were generated from the peripheral blood of these patients as well as one patient with prostate cancer. These lines also recognized whole, processed PSA in the context of HLA-DRB1*1501. This study will be instrumental in understanding the interaction between circulating self-reactive T cells, organ-specific autoimmunity, and antitumor immune response. The use of these peptides for the immunotherapy of prostate cancer is under investigation. 相似文献
13.
14.
Cathleen G. Jones Pamela B. Yang Victor T. Wilcox Keith D. Burau Nachum Dafny 《Journal of neural transmission (Vienna, Austria : 1996)》2014,121(5):457-468
The psychostimulants considered the gold standard in the treatment of attention deficit hyperactivity disorder, one of the most common childhood disorders, are also finding their way into the hands of healthy young adults as brain augmentation to improve cognitive performance. The possible long-term effects of psychostimulant exposure in adolescence are considered controversial, and thus, the objective of this study was to investigate whether the chronic exposure to the psychostimulant amphetamine affects the behavioral diurnal rhythm activity patterns of female adolescent Wistar-Kyoto (WKY) rat. The hypothesis of this study is that change in diurnal rhythm activity pattern is an indicator for the long-term effect of the treatment. Twenty-four rats were divided into two groups, control (N = 12) and experimental (N = 12), and kept in a 12:12-h light/dark cycle in an open-field cage. After 5–7 days of acclimation, 11 days of consecutive non-stop behavioral recordings began. On experimental day 1 (ED1), all groups were given an injection of saline. On ED2 to ED7, the experimental group was injected with 0.6 mg/kg amphetamine followed by 3 days of washout from ED8 to ED10, and amphetamine re-challenge on ED11 similar to ED2. The locomotor movements were counted by the computerized animal activity monitoring system, and the cosinor statistical test analysis was used to fit a 24-h curve of the control recording to the activity pattern after treatment. The horizontal activity, total distance, number of stereotypy, vertical activity, and stereotypical movements were analyzed to find out whether the diurnal rhythm activity patterns were altered. Data obtained using these locomotor indices of diurnal rhythm activity pattern suggest that amphetamine treatment significantly modulates the locomotor diurnal rhythm activity pattern of female WKY adolescent rats. 相似文献
15.
16.
17.
18.
Min‐Geol Lee Yu‐Huei Huang Joo‐Heung Lee Seung‐Chul Lee Tae‐Gyun Kim Derrick Chen‐Wee Aw Weibin Bao Cathleen Michelle A. Dee Adriana Guana Tsen‐Fang Tsai 《The Journal of dermatology》2019,46(9):752-758
The 52‐week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient‐reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double‐blind, phase IIIb study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90% or more improvement in Psoriasis Area and Severity Index (PASI 90) with secukinumab versus ustekinumab at week 16 (78.3% vs 35.9%, P = 0.0010) and at week 52 (60.9% vs 33.3%, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5% vs 10.3%, P = 0.0029) and at week 52 (30.4% vs 12.8%, P = 0.0704). The median time to achieve 50% improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7% and 84.6% of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis. 相似文献
19.
20.